Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 244 participants.
Also called NCT02357615
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 244 participants
- Sponsor
- Shanghai Shyndec Pharmaceutical Co., Ltd.
- Registry
-
NCT02357615
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT02357615. Randomized; no masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2015-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure
- Condition
- Essential Hypertension
- Intervention (Drug)
- nifedipine CR tablets (Xin Ran)
- Intervention (Drug)
- Adalat
- Lead sponsor
- Shanghai Shyndec Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct02357615- Content hash
05fc2aa4786a30b942f4304be18bd38d9bf3ec9fb4c7260ebc30441a900acec1